Presentations

      Measuring Mouse Abdominal Aorta Dimensions In Vivo: A Comparison Between (3D) Ultrasound And Micro-CT

      Trachet, B.; Segers, P.; Claes, F.; Berges, A.
      Conference date
      Aug 1, 2010
      Conference name

      6th World Congress on Biomechanics
      Link to more information
      Topic
      Summary

      Introduction: Mouse models are very useful to study the origin and progression of cardiovascular diseases. An important component of the follow-up process, however, involves in vivo imaging of cardiovascular structures. Recently, this has become possible due to the introduction of high-frequency ultrasound (US) technology and specific contrast agents for micro-CT. In order to test the comparability of these imaging modalities, we compared abdominal aortic (AA) diameter values measured in 9 mice at 4 different time points using 3 in vivo methods: in vivo micro-CT, 3D US, and M-mode US. Methods: Nine Apolipoprotein E-deficient mice (7-weeks-old) were scanned after 0, 8, 12, and 19 days. At each time point, m-mode measurements were taken using Vevo770 equipment (Visualsonics) to assess the AA diameter at the proximal, middle, and distal zone (marked by the branching of celiac and left renal arteries, respectively, with each zone having an average length of about 5 mm). A 3D reconstruction was performed using transversal b-mode images of the AA over a range of 2 cm. Subsequently, the animals were IV. Injected with 0.0075 ml/g Exia 160 XL (Binitio) and scanned in a micro-CT (Skyscan 1076). The contrast allowed us to discriminate the aorta from the surrounding tissues. For each AA zone, diastolic and systolic diameters were measured and the average diameter was calculated. The b-mode images were segmented using the edge detection algorithm of the us software, and the micro-CT images were manually segmented in mimics. For both 3d geometries, an average value of the AA diameter was calculated for each zone. Statistical comparison (Univariate analysis of variance or paired samples t-test) was performed using the software package SPSS. Results and discussion: all AA diameters increased significantly over time.

      Related Publications

      Cigarette smoke enhances abdominal aortic aneurysm formation in angiotensin II-treated apolipoprotein E-deficient mice

      Pre-clinical Toxicology

      Tobacco Heating System 2.4 has less harmful impact on 2D bone co-culture system than cigarette smoke

      Pre-clinical Toxicology

      Characterizing the Genotoxic Potential of E-Cigarette Components In Vitro

      Pre-clinical Toxicology

      Evaluation of Chronic Toxicity and Carcinogenicity of Flavored E-Vapor Aerosols in an 18-Month Inhalation Study in A/J Mice

      Pre-clinical Toxicology

      Toxicological Assessment of Highly Mentholated Reduced-Risk Tobacco Products in Sprague Dawley Rats Following Sub-Chronic Inhalation Exposure

      Pre-clinical Toxicology

      Exposure to a Heated Tobacco Product Aerosol Is Associated with Lower Activity of Hepatic Cytochrome P450 Enzymes and Reduced Alteration in Clozapine Metabolism Than Exposure to Cigarette Smoke

      Pre-clinical Toxicology

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.